Innovation-driven biopharma startup Lamark Biotech has secured Rs 6.5 crore in a pre-Series A funding round. IAN Group led the investment, with participation from IAN Alpha Fund, powered by BioAngels, along with Dr. Vinayender Tulla, Dr. Nita Roy, and Venkataraman KNK—domain experts and angel investors from IAN.

Dr. Vaibhav Bhatia, a biochemist and entrepreneur, founded Lamark Biotech in 2018 with a vision to revolutionise drug delivery for chronic and life-altering conditions. The company’s proprietary ProteoStrong platform stabilises delicate protein-based drugs, such as insulin, monoclonal antibodies, and enzymes without changing their molecular structure, thus addressing a major challenge in biologics: reducing reliance on cold-chain logistics.

“We’re accelerating our thermostable insulin program and expanding ProteoStrong to more critical therapeutics using this resource. Our priority is clear to make safe and high-efficacy biologics for all. We believe, ‘if it is not accessible, it not a medicine’,” said Vaibhav Bhatia, who also serves as the company’s CEO.

Padmaja Ruparel, Co-founder of IAN Group, noted, “Investment in Lamark represents IAN’s investment strategy to invest and grow innovations that solve real problems. The solution is critical in low-resource environments, with Lamark’s thermostable biologics which can make critical treatments accessible at a low cost for millions of people, both in India and globally.”

Headquartered in Ahmedabad and operating out of the Venture Centre at NCL Innovation Park in Pune, Lamark is developing a novel class of temperature-resilient biologics capable of retaining effectiveness even in extreme conditions. These are particularly well-suited for regions lacking cold storage infrastructure.

With its flagship program, InsulinStrong, Lamark aims to capture a share of India’s Rs 4,000 crore insulin market and expand into Southeast Asia and the UAE. The company is also advancing applications of its platform in diabetic eye disease and cancer immunotherapy.

Over the next two years, Lamark plans to file international patents, launch early-stage clinical trials, and forge collaborations with pharmaceutical firms, CDMOs, and global health organisations.

Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!